– CANADA, Montreal – Morphocell Technologies, a pioneer in advanced tissue engineering solutions for organ-threatening diseases, announced the appointment of Dr. Paul Wotton to its Board as an Independent Director.
About Dr. Paul K. Wotton
His career highlights include significant achievements as a CEO and board member across various biotech companies. Currently, he serves as CEO and Chairman of the Board of RBL LLC, the biotech venture creation studio recently launched by Rice University in Houston’s Texas Medical Center, and serves on the Board of Directors of Vericel Corporation, Cynata Therapeutics, and Kytopen. An EY Entrepreneur of the Year for 2014 (NJ), His extensive background in advancing therapeutic biotechnologies is complemented by his leadership in encapsulated therapies and his ability to secure high-profile transactions and impactful partnerships, such as those with Vertex Pharmaceuticals and M.D. Anderson during his tenure at Obsidian Therapeutics. Earlier, while CEO of Siglion Therapeutics, Inc., he implemented the partnership leading to the eventual acquisition of the company by Eli Lilly and Company. Dr. Wotton is also the former President, CEO, and director of Ocata Therapeutics, Inc. (until its acquisition by Astellas Pharma US, Inc. in 2016), the former President, CEO, and director of Antares Pharma, Inc., a publicly traded biopharmaceutical company (2008-2014), a former director of Veloxis Pharmaceuticals, acquired by Asahi Kasei, and has held senior level positions at Penwest Pharmaceuticals, Eurand International BV, Abbott Laboratories and Merck, Sharp and Dohme. His guidance will reinforce Morphocell’s strategic direction as the company continues its mission to transform patient outcomes through groundbreaking treatments for liver and other organ-threatening conditions.
Dr. Paul Wotton said, “I look forward to working with the impressive team at Morphocell to address the growing healthcare challenge of rapidly increasing demand for organ transplantation. Recent advances in regenerative medicine have created an opportunity to improve transplantation treatment significantly and, with its innovative science and “off-the-shelf” potential, Morphocell is in a leading position to provide more accessible therapeutic options for patients. It is an exciting time to join this transformative company.”
Dr. Paul Wotton holds a Ph.D. in pharmaceutical sciences from the University of Nottingham, an M.B.A. from Kingston Business School, and a Bachelor’s in Pharmacy with honors from University College London. His profound expertise and strategic focus will play a pivotal role as Morphocell continues to advance its tissue engineering platform and prepare for the next phase of growth. This appointment marks an exciting chapter for Morphocell as the company leverages Dr. Wotton’s leadership and expertise to shape its future and impact the field of regenerative medicine.
About Morphocell Technologies
Morphocell Technologies is a leader in tissue engineering and cell therapy, dedicated to developing transformative treatments for patients facing severe organ deficiencies, beginning with liver disease. Utilizing its innovative platform, Morphocell aims to be a global pioneer in regenerative medicine, offering innovative stem cell-based solutions that revolutionize organ replacement therapy and answer the most pressing unmet medical needs.
For more: https://www.morphocell.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.